REVIEW: Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline

Acinetobacter baumannii complex (ABC) causes severe infections such as pneumonia and septic shock, yet therapeutic options—particularly for carbapenem‑resistant strains (CRAB)—remain scarce amid rising antimicrobial resistance. This review synthesizes the in‑vitro activity, mechanisms of action and clinical evidence behind the newly approved agents cefiderocol and sulbactam‑durlobactam, and profiles four late‑stage investigational candidates—BV‑100, cefepime‑zidebactam, zosurabalpin and OMN6—that may soon expand the treatment arsenal. 

READ REVIEW PUBLISHED 7 February 2025.

Authors: Noayna Arshad, Wael Azzam, Marya D. Zilberberg and Andrew F. Shorr

Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline Download

 

More To Explore

Contact Us

Reach US

Linkedin Twitter

A-2-Z - Digital Accessibility and Marketing

 

Omnix Medical Ltd. is committed to making its website and all its electronic information easier to use and more accessible for people with disabilities. The company’s website was created and/or updated according to the provisions of the Equal Rights for People with Disabilities Law, 5748-1998, and the delegated legislation stemming from it, and it fully complies with the W3C Web Content Accessibility Guidelines 2.0, AA level.


Omnix Medical Ltd. will continue its efforts to constantly improve the accessibility of its website and information in the belief that it is our collective moral obligation to allow seamless, accessible, and unhindered use also for those of us with disabilities.

  

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).